Clinical Trial Update: Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis) [Phase 3]

View source ↗

Summary

This document reports results from a double-blind extension of the HORIZON Phase 3 trial evaluating zoledronic acid for fracture prevention in postmenopausal os…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2011-04-20